ClinicalTrials.gg
TerminatedNCT05170269PreCyssionUpdated Mar 10, 2025

Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)

A Phase 3 interventional study of BT097 in Congenital Cytomegalovirus Infection, sponsored by Biotest. Terminated at 5 sites in Germany. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-03-10.

Sponsored by Biotest (part of Grifols) · Phase 3, Interventional, and Prevention

How we know

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Cytomegalovirus Infections with a site in Germany — 1 open to participants now, 1 under way, 1 of them phase 3. Cytomegalovirus Infections · Germany.

Enrollment
13th of 13
48 · median 149
Started
2021
with 1 other
Phase 3
8 of 16
1 open now
Registered
16th of 16
by date
Lead sponsor
1 of 16
Biotest

Among the 16 studies in Cytomegalovirus Infections with a site in Germany, this one is the 13th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2021, is one of 8 in phase 3, and was the 16th registered.

Cytomegalovirus Infections

370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.

Browse Cytomegalovirus Infections studies →

Open to participants now

1 of the 16 studies in Cytomegalovirus Infections with a site in Germany is open now. Recruiting first, the newest first:

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Cytomegalovirus Infections with a site in Germany, or all of them as a file.
02

Study summary

A phase 3, open-label, single-arm, prospective, multi-center trial of Cytotect CP Biotest (BT097) for prevention of maternal-fetal CMV transmission after primary maternal CMV infection. The main purpose of the trial is to demonstrate efficacy and safety of Cytotect CP Biotest in preventing maternal-fetal transmission of cytomegalovirus (CMV).

03

Conditions studied

  • Congenital Cytomegalovirus Infection

Keywords

  • Cytomegalovirus
  • Pregnancy
  • CMVIG
  • maternal CMV infection
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written obtained from subjects indicating that they understand the purpose of and procedures required for the trial and are willing to participate in it
  • Pregnant women, age 18 to 45 years
  • Pregnant women at trial entry with gestational age ≤14 weeks; pregnancy after in-vitro fertilization permitted
  • Detection of early primary CMV infection

Exclusion criteria

Exclusion Criteria:

  • Women with current multiple pregnancy
  • History of severe pre-eclampsia or severe gestational hypertension (GHTN), which required medical intervention. Definition according to AWMF guideline (AWMF, 2019)
  • Presence of severe disease impairing course of pregnancy (e.g. diabetes, epilepsy, cancer)
  • Congenital or acquired disease
  • Known (e.g., transplanted patients) or immunodeficient condition
  • Known infection with or C, or from the medical history or active infection at screening as assessed by respective virus serology
  • Maternal CMV infection prior to this pregnancy (preconceptional CMV infection)
  • Covid-19 infection at time of inclusion
  • Any signs or symptoms indicating an increased risk of abortion or premature labor or has known negative effect on fetus with exception of a CMV infection
  • Active infection according to TORCH serology with exception of CMV in the assessment of the investigator
  • Known major fetal anomalies or demise
  • Intolerance to proteins of human origin or known allergic reactions to components of the trial product
  • Selective absolute IgA deficiency or known antibodies to IgA
  • Known pre-existing risk factors for thrombotic events
  • Known renal insufficiency with serum creatinine levels >1.4 mg/dL and proteinuria (albuminuria) at screening (≥30 mg/dL or dipstick reading of 1+ and greater)
  • Participation in another clinical trial within 90 days before entering the trial or during the trial
  • Women who are dependent on trial site staff, on Biotest AG or its authorized representatives
  • Inability or lacking motivation to participate in the trial
  • Medical condition, laboratory finding, or physical examination finding that in the opinion of the investigator precludes participationInability or lacking motivation to participate in the trial
  • Eligibility for a subgroup where enrollment was stopped
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    BT097

    Subjects will receive BT097 200 U per kg of maternal body weight intravenously every 2 weeks until at least GW 17

    Drug: BT097

Interventions

  • DrugBT097

    Subjects will receive BT097 200 U per kg of maternal body weight intravenously every 2 weeks until at least GW 17

    Also known as: Cytotect CP Biotest 100 U/mL solution for infusion

06

What researchers measure

Primary outcomes

  1. To determine the overall rate of maternal-fetal transmission at the time of amniocentesis (week 20 [-1 week / +2 weeks] of gestation)

    To determine the overall rate of maternal-fetal transmission at the time of amniocentesis

    Time frame: Gestational week 19 - week 22

Secondary outcomes

  1. Subgroups: (1) Subjects with periconceptionally acquired infection or (2) Subjects with infection acquired during first trimester

    To determine the rate of maternal-fetal transmission at the time of amniocentesis

    Time frame: Gestational week 20 +-1 Week

  2. To determine maternal CMV viral load (copies/ml)

    Number of CMV-DNA copies (copies/mL) and corresponding absolute and percentage changes from baseline, until gestational week (GW) 30

    Time frame: until gestational week 30

  3. To determine maternal anti-CMV IgG Levels (U/ml)

    Maternal anti-CMV IgG Levels (U/ml), absolute and percentage changes from baseline

    Time frame: until gestational week 30

  4. To determine maternal anti-CMV IgG avidity (%)

    Number/percentage of subjects with Low, Intermediate, High avidity

    Time frame: until gestational week 30

  5. To determine maternal anti-CMV IgM index (Index)

    Number/percentage of subjects with non-reactive, indeterminate and reactive cut-off index (COI)

    Time frame: until gestational week 30

  6. To determine soluble fms-like tyrosine kinase 1 (sFlt-1) concentration in maternal serum

    Number/percentage of subjects with high (≥1504 pg/mL) or low (\<1504 pg/mL) values

    Time frame: until gestational week 30

  7. To evaluate vitality of the fetuses/newborns

    Number/percentage of subjects with Normal / Abnormal Not Clinically Significant / Abnormal Clinically Significant results per parameter and visit

    Time frame: until date of delivery

  8. To evaluate growth of the fetuses/newborns

    Number/percentage of subjects with Normal / Abnormal Not Clinically Significant / Abnormal Clinically Significant results per parameter and visit

    Time frame: Until date of delivery

  9. To evaluate the rate of congenital CMV infection at delivery or within the first 3 days after delivery

    To evaluate the rate of congenital CMV infection at delivery or within the first 3 days after delivery

    Time frame: Date of Delivery + 3 days

  10. To measure the number of CMV-DNA copies in the urine of newborns

    To measure the number of CMV-DNA copies in the urine of newborns

    Time frame: Date of Delivery

  11. To assess the number, severity, causality, outcome, and seriousness of all adverse events (AEs)/ treatment-emergent AEs (TEAEs)/ AEs of special interest until delivery (+3 days) in both mother and fetus/newborn

    To assess the number, severity, causality, outcome, and seriousness of all adverse events (AEs)/ treatment-emergent AEs (TEAEs)/ AEs of special interest until delivery (+3 days) in both mother and fetus/newborn

    Time frame: Date of Delivery + 3 days

07

Study locations

5 sites
  • 4906
    Berlin, 13353, Germany
  • 4903
    Bonn, 53127, Germany
  • 4902
    Erlangen, 91054, Germany
  • 4901
    Tuebingen, 72076, Germany
  • 4905
    Wasserburg am Inn, 83512, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Nov 2023, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2021
First posted
Dec 27, 2021
StartActual
Nov 17, 2021
Primary completionActual
Nov 19, 2023
CompletionActual
Mar 29, 2024
Last update
Mar 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05170269
Lead sponsor
Biotest
Responsible party
Sponsor
First posted
Dec 27, 2021
Start date
Nov 17, 2021
Primary completion
Nov 19, 2023
Completion
Mar 29, 2024
Last update
Mar 10, 2025

Study contacts

Karl O Kagan, Prof
principal investigator · Universitätsklinik Tuebingen - Frauenklinik; 72076 Tübingen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion